Takeheart Health Check      

202 Cochrane A.
Effectiveness and efficiency. Random reflections on health services.
London Nuffield Provincial Hospital Trusts 1972.

203 Light DW.
Effectiveness and efficiency under competition: the Cochrane Test.
BMJ 1991; 303: 1253-4

204* Noble J, Chilton R
. Total Knee Replacement
BMJ 1991; 303: 262

205* Millett BR.
Harmogen
Personal communication 19/12/91

206* Kewis B.
Lipids and the general practitioner's part in preventing coronary heart disease
Mims Magazine 15/11/91 21-28

207* Weisburst M, Self T, Peace R, Cooper J.
Jaundice and rash associated with use of phenobarbitol and hydrochlorothiazide.
Southern Medical Journal 1976; 69: 126-127

208* Nolan PJ, D'Arcy G.
Triamterine drug fever and hepatitis
The Medical Journal of Australia 1987; 147: 262

209* Eitzen AC.
Report of death following administration of triamterine.
J Kansas Med Soc 1966; 8: 454-5

210* Dawson J.
Sexual Politics of the Heart
BMJ 1991; 303: 1354

211* Beecham L.
£437 million up in smoke each year
BMJ 1991; 303: 1355

212 The Smoking Epidemic - Counting the cost. 1991
HEC, Hamilton House, Mabledon Place, WC1H 9T

213* Lewis B.
Preventive medicine in primary care: management of hyperlipidaemia.
Br Journ Gen Prac 1992; 42: 47-50

214 Lewis B, Rose G.
Prevention of coronary heart disease: putting theory into practice.
J R Coll Physicians Lond 1991; 25: 21-26

215 RCGP
Guidelines for the management of hyperlipidaemia in general practice - towards the primary prevention of coronary heart disease.
Occasional Paper 55 London RCGP 1992

216 Fielding JE.
Smoking: health effects and control.
N Engl J Med 1985; 313: 491-498, 555-561

217 Collins R, Peto R, MacMahon S, et alia
Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure; overview of randomised drug trials in their epidemiological context.
Lancet 1990; 2: 827-838

218 SHEP Cooperative research group. Probstfield JL.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.
JAMA 1991; 265: 3255-3264

219 Dahlof B, Lindholm LH, Hansson L, et alia.
Morbidity and mortality in the Swedish trial in old patients with hypertension. (STOP-Hypertension)
Lancet 1991; 338: 1281-1285

220 Samuelsson O, Andersson OK, Penmert K, et alia
Cardiovascular mortality in relation to blood pressure control and changes in blood pressure and serum cholesterol during long term treatment of hypertension. Results from the primary prevention trial in Goteborg, Sweden.
JAMA 1987; 258: 1768-1776

221 Hjerrmann I, Helgeland A, Holme I, et alia
The association between blood pressure and serum cholesterol in healthy men: the Oslo study.
J Epidemiol Community Health 1978; 32: 117-123

222 Williams RR, Hunt SC, Hopkins PN.
Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension.
JAMA 1988; 259: 3579-3586

223 Lewis B.
Hyperlipdaemia
In Metabolic and molecular bases of acquired disease. London: Bailliere Tindall, 1990.

224 Peto R, Yusuf S, Collins R.
Cholesterol-lowering trials in their epidemiological context.
Circulation 1985; 72: 451

225 Holme I.
An analysis of randomised trials, evaluating the effects of cholesterol reduction on total mortality and coronary heart disease incidence.
Circuation 1990; 82: 1916-1924

226 Yusuf S, Wittes J, Friedman L.
Overview of results of randomised clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification.
JAMA 1988; 260: 2259-2263

227 Brown G, Albers JJ, Fisher LD.
Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B.
N Engl J Med 1990; 323: 1289-1298

228 Buchwald H, Varco RL, Matts JP.
Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia.
N Engl J Med 1990; 323: 946-955

229 Watts JF, Lewis B, Brunt JNM, et alia
Favourable effects on coronary heart disease of lipid lowering diet, or diet cholestyramine, in a unifactorial randomised control trial: the St Thomas' hospital atheroma trial (STARS).
Lancet 1992; 339;

230 Rossouw JE, Lewis B, Rifkind BM.
The value of lowering cholesterol after myocardial infarction.
N Engl J Med 1990; 323: 1112-1119

231 Lewis B.
Safety aspects of cholesterol lowering: total mortality, specific side effects and random associations.
Lipid Review 1992; 5: 41-47

232 Strandberg TE, Salomaa VV, Naukkarinen VA, et alia
Longterm mortality after five year multifactorial primary prevention of cardiovascular diseases in middle aged men.
JAMA 1991; 266: 1225-1229

233 Woolf N, Chait A.
Atherosclerosis: pathogenesis and factors affecting its progression
In Metabolic and molecular bases of acquired disease. London: Bailliere Tindall, 1990

234* Frater A, Costain D.
Any better? Outcome measures in medical audit.
BMJ 1992; 304: 519-520

235 Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zubkoff M.
The medical outcome study: an application of methods for monitoring the results of medical care.
JAMA 1989; 262: 925-30

236 Oliver MF.
Doubts about preventing coronary heart disease.
BMJ 1992; 304: 393-4

237 Standing Medical Advisory Committee.
Blood cholesterol testing: the cost-effectiveness of opportunistic cholesterol testing. Report to the Secretary of State for Health.
London: Department of Health 1990

238 Tjimstra T.
The psychological and social implications of serum cholesterol screening.
International Journal of Risk and Safety in Medicine. 1990; 1: 29-44

239 Marteau TM.
Reducing the psychological costs.
BMJ 1990; 301: 26-8

240 Sharp I.
An Agenda for Nutrition Education in the 1990's
In: Hurren C, Black A eds. The food network: achieving a healthy diet by 2000: proceedings of a conference. London: Smith Gordon 1991: 83-111

241 Davies MJ, Krikler DM, Katz D.
Atherosclerosis: inhibition or regression as therapeutic possibilities.
British Heart Journal 1991; 65: 302-10

242 Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, et alia.
Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St Thomas' atherosclerosis regression study (STARS).
Lancet 1992; 339: 563-9

243* Goodwin JF, Sharp I.
Preventing Coronary Heart Disease.
Letter BMJ 1992; 304: 1057

244* Cohen DL, Fowliw S.
Changing lifelong habits of elderly people.
Letter BMJ 1992; 304: 1055

245 Dressler W, Evans P, Pereira-Gray D.
Status incongruance and serum cholesterol in an English general practice.
Soc Sci Med 1992; 34: 757-762

246 Dobson A, Alexander H, Heller R, Lloyd D.
How soon after quitting smoking does the risk of heart attack decline?
J Clin Epidemiol 1991; 44: 1247-1253

247* McMurdo MET.
Time to halt the screening bandwagon?
Care of the Elderly May 1992 191

248* Staff Reporter
"Health Test Franchises Alarm Doctors"
The Guardian 18/6/92 page 6

249* Guidelines for Near-patient Tests
Royal College of General Practitioners, Connections June 1992

250* Ravnskov U.
Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.
BMJ 1992; 305: 15-19